Overview

Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of BAY63-2521 in patients with pulmonary hypertension and stable treatment of sildenafil 20 mg.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Riociguat
Sildenafil Citrate